glp-1 news today november 6 2025 China approves Pfizer drug for weight loss Frontiers | GLP-1 agonists and

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.

Side Effects: As a GLP-1 therapy, common side effects are typically gastrointestinal, including nausea, vomiting, and diarrhea.

Learn what patients and prescribers should know about lean mass, protein, and exercise.

However, there was progress in the UK where the government announced Scotland CardioMetabolic Impact Study (SCoMIS) , a pioneering Real-World study, which will provide Wegovy to between 3,000-5,000 people living with Obesity in Scotlands poorest areas free of charge during a three year study [11] Despite FDA phasing out enforcement discretion that allowed GLP-1 compounding during shortages - and setting May 2025 deadlines for compounding to cease - compounding has continued beyond this deadline [12]

Introduced in the twenty-first century, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits

A mechanistic guide to this next-generation metabolic peptide.